688176.SHG Jiangsu Yahong Meditech Co. Ltd.
- Market cap
- CNY 6.41B
- P/E
- -
- P/B
- 4.93x
- ROE
- -39.2%
- Dividend yield
- 0.06%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688176.SHG undervalued?
Graham numberThe Graham number of Jiangsu Yahong Meditech Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangsu Yahong Meditech Co. Ltd. fundamental analysis
No fundamental analysis for Jiangsu Yahong Meditech Co. Ltd. yet.
Jiangsu Yahong Meditech Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangsu Yahong Meditech Co. Ltd.
Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. It develops APL-1702, a photodynamic drug-device combination product for the treatment of high-grade squamous intraepithelial lesions of the cervix and for HPV viral clearance; APL-2302, an oral small-molecule inhibitor of the deubiquitinating enzyme ubiquitin-specific protease 1 (USP1) for the treatment of ovarian and breast cancer; APL-…
Full company profileJiangsu Yahong Meditech Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangsu Yahong Meditech Co. Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | 0.00 | 0.00 | 4.57K | 26.1K | 13.8M | 202M | 277M | 345M |
| Gross Profit | -388K | 0.00 | -205K | -1.19M | -1.81M | 10.8M | 151M | 277M | 262M |
| Operating Income | -59.9M | -172M | -247M | -238M | -248M | -404M | -384M | -431M | -496M |
| EBITDA | -59.5M | -171M | -246M | -232M | -240M | -391M | -365M | -421M | -485M |
| Net Income | -59.9M | -172M | -247M | -235M | -247M | -400M | -384M | -419M | -482M |
| EPS | - | -0.37 | -0.54 | -0.51 | -0.43 | -0.67 | -0.65 | -0.75 | -0.84 |
| Balance Sheet | |||||||||
| Total Assets | 66.1M | 72.7M | 849M | 3.10B | 2.87B | 2.63B | 2.22B | 2.06B | 1.79B |
| Total Liabilities | 18.9M | 44.0M | 42.9M | 86.0M | 103M | 243M | 253M | 494M | 586M |
| Shareholders' Equity | 47.2M | 28.8M | 806M | 3.01B | 2.77B | 2.39B | 1.97B | 1.58B | 1.23B |
| Cash & Short-term Investments | 28.8M | 56.2M | 799M | 2.98B | 2.74B | 2.33B | 1.29B | 779M | 313M |
| Total Debt | 77.8K | 87.8K | 5.77M | 17.4M | 18.7M | 124M | 116M | - | - |
| Cash Flow | |||||||||
| Operating Cash Flow | -52.8M | -88.8M | -126M | -172M | -242M | -398M | -425M | -412M | - |
| Capital Expenditure | 8.49M | 750K | 14.3M | 42.4M | 26.6M | 102M | 5.79M | 19.1M | 69.4M |
| Free Cash Flow | -61.3M | -89.6M | -140M | -214M | -269M | -500M | -431M | -431M | -586M |
| Ratios | |||||||||
| ROE | -126.9% | -599.6% | -30.7% | -7.8% | -8.9% | -16.8% | -19.5% | -26.6% | -39.2% |
| ROA | -90.7% | -237.0% | -29.1% | -7.6% | -8.6% | -15.2% | -17.3% | -20.4% | -26.9% |
| Net Profit Margin | - | - | - | -5,136,625.8% | -944,816.2% | -2,911.5% | -190.5% | -151.3% | -139.7% |
| Debt to Equity | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.05x | 0.06x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jiangsu Yahong Meditech Co. Ltd. dividends
- Dividend yield
- 0.06%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 4.08M | 0.01 | - |
| 2024 | CNY 2.49M | 0.00 | - |
| 2023 | CNY 412K | 0.00 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | CNY 361K | 0.00 | - |
| 2019 | CNY 20.1K | 0.00 | - |
| 2018 | 122K | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Jiangsu Yahong Meditech Co. Ltd.
- Insiders 40.10%
- Institutions 1.96%
- Public & others 57.95%
- Shares outstanding 572M
- Free float 369M
Jiangsu Yahong Meditech Co. Ltd. company profile
- Company name
- Jiangsu Yahong Meditech Co. Ltd.
- Ticker
- 688176.SHG
- ISIN
- CNE100005XW0
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 497
- Fiscal year end
- December
- Address
- Building B, Qiantan World Trade Center, Shanghai, China, 200126
- Phone
- 86 21 6858 3863
- Website
- asieris.cn
About Jiangsu Yahong Meditech Co. Ltd.
Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. It develops APL-1702, a photodynamic drug-device combination product for the treatment of high-grade squamous intraepithelial lesions of the cervix and for HPV viral clearance; APL-2302, an oral small-molecule inhibitor of the deubiquitinating enzyme ubiquitin-specific protease 1 (USP1) for the treatment of ovarian and breast cancer; APL-2501 for the treatment of ovarian cancer; AT-018 for the treatment of breast cancer; and AT-021 for the treatment of breast cancer and other solid tumors. The company also develops APL-1706 and APLD-2304 for non-muscle-invasive bladder cancer (NMIBC) diagnosis and surgery; APL-1202 for Untreated intermediate-risk NMIBC and neoadjuvant therapy before MIBC; and APL-2401 for urinary tumors. In addition, it develops APL-1202 for the treatment of free-living amoeba infection; APL-1401 for moderate to severe active ulcerative colitis; and APL-2301, an antibiotic for Acinetobacter baumannii infection. The company was incorporated in 2010 and is based in Shanghai, China.
Jiangsu Yahong Meditech Co. Ltd. management
7- Dr. Ke PanFounder, Chairman & CEO · born 1968
- Mr. Baohua ChenExecutive VP of Finance, Employee Representative Director & Board Secretary · born 1975
- Mr. Chengfeng ZhuangDeputy GM & Director · born 1963
- Xiong YuanHead of the Accounting Department
- David Wilson Ph.D.Senior Vice President of BD
- Dr. Chen YuSenior VP of Biological Research, Drug Discovery Division & Head of Translational Medicine Research
- Mr. Yang ZhaoSenior Vice President of Business Development